351 related articles for article (PubMed ID: 30764623)
1. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
2. Current data on the efficacy of prophylactic HPV vaccination in the primary prevention of cervical lesions.
Sehnal Borek; Driák Daniel; Džubáková Nipčová Monika; Sláma Jiří
Ceska Gynekol; 2022; 87(2):124-130. PubMed ID: 35667864
[TBL] [Abstract][Full Text] [Related]
3. [The 2-dose schedule of HPV vaccines in young adolescents].
Sehnal B; Neumannová N; Driák D; Halaška M; Kotoulová M; Sláma J
Ceska Gynekol; 2015 Jan; 80(1):50-6. PubMed ID: 25723080
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic HPV vaccination].
Freitag P
Ceska Gynekol; 2007 Jan; 72(1):38-41. PubMed ID: 17357348
[TBL] [Abstract][Full Text] [Related]
6. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
[TBL] [Abstract][Full Text] [Related]
8. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
9. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
10. HPV-vaccination against cervical carcinoma: will it really work?
Gross G
Med Microbiol Immunol; 2007 Sep; 196(3):121-5. PubMed ID: 17318575
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of introducing a nonavalent HPV vaccination.
Bogani G; Taverna F; Lombardo C; Signorelli M; Chiappa V; Casarin J; Scaffa C; Leone Roberti Maggiore U; Recalcati D; Ditto A; Martinelli F; Borghi C; Perotto S; Ferrero S; Lorusso D; Raspagliesi F
Int J Gynaecol Obstet; 2018 Sep; 142(3):338-342. PubMed ID: 29858884
[TBL] [Abstract][Full Text] [Related]
12. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
14. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
15. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
[TBL] [Abstract][Full Text] [Related]
16. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily.
Capra G; Giovannelli L; Matranga D; Bellavia C; Guarneri MF; Fasciana T; Scaduto G; Firenze A; Vassiliadis A; Perino A
Hum Vaccin Immunother; 2017 Aug; 13(8):1839-1843. PubMed ID: 28594305
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.
Wang R; Pan W; Jin L; Huang W; Li Y; Wu D; Gao C; Ma D; Liao S
Cancer Lett; 2020 Feb; 471():88-102. PubMed ID: 31812696
[TBL] [Abstract][Full Text] [Related]
18. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule.
Brotherton JM
Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
